208 related articles for article (PubMed ID: 16000000)
1. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA
J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000
[TBL] [Abstract][Full Text] [Related]
2. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.
Thompson AM; Connolly CJ; Hamby JM; Boushelle S; Hartl BG; Amar AM; Kraker AJ; Driscoll DL; Steinkampf RW; Patmore SJ; Vincent PW; Roberts BJ; Elliott WL; Klohs W; Leopold WR; Showalter HD; Denny WA
J Med Chem; 2000 Nov; 43(22):4200-11. PubMed ID: 11063616
[TBL] [Abstract][Full Text] [Related]
3. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
4. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.
Hamby JM; Connolly CJ; Schroeder MC; Winters RT; Showalter HD; Panek RL; Major TC; Olsewski B; Ryan MJ; Dahring T; Lu GH; Keiser J; Amar A; Shen C; Kraker AJ; Slintak V; Nelson JM; Fry DW; Bradford L; Hallak H; Doherty AM
J Med Chem; 1997 Jul; 40(15):2296-303. PubMed ID: 9240345
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).
Thompson AM; Rewcastle GW; Boushelle SL; Hartl BG; Kraker AJ; Lu GH; Batley BL; Panek RL; Showalter HD; Denny WA
J Med Chem; 2000 Aug; 43(16):3134-47. PubMed ID: 10956222
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development.
Magnusson P; Rolny C; Jakobsson L; Wikner C; Wu Y; Hicklin DJ; Claesson-Welsh L
J Cell Sci; 2004 Mar; 117(Pt 8):1513-23. PubMed ID: 15020678
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Garofalo A; Farce A; Ravez S; Lemoine A; Six P; Chavatte P; Goossens L; Depreux P
J Med Chem; 2012 Feb; 55(3):1189-204. PubMed ID: 22229669
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
13. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
16. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
17. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
18. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
19. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
20. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
